Eli Lilly Advances ALS Drug Development with Verge Genomics’ AI-Powered Target Identification – Draper Decentralized – 12.3.24
Verge Genomics and Eli Lilly expand their ALS collaboration, with Verge’s AI-driven CONVERGE® platform identifying therapeutic targets. This milestone triggers milestone payments and potential royalties for Verge as Lilly moves forward with ALS drug development.